scholarly journals Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies

2020 ◽  
Vol 10 ◽  
Author(s):  
Sandra Carvalho ◽  
Catarina M. Abreu ◽  
Dylan Ferreira ◽  
Luís Lima ◽  
José A. Ferreira ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Phenotypic Analysis ◽  
Liquid Biopsies ◽  
Exfoliated Cells ◽  
Sialyl Tn

Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction

2017 ◽  
Vol 22 (5-6) ◽  
pp. 389-401 ◽  
Author(s):  
Yu Yang ◽  
Catherine R. Miller ◽  
Antonio Lopez-Beltran ◽  
Rodolfo Montironi ◽  
Monica Cheng ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Response ◽  
Response Prediction ◽  
Next Generation ◽  
Liquid Biopsies ◽  
Treatment Response Prediction

scholarly journals Circulating Cell-Free DNA in Liquid Biopsies as Potential Biomarker for Bladder Cancer: A Review

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1448
Author(s):  
Raquel Herranz ◽  
Julia Oto ◽  
Emma Plana ◽  
Álvaro Fernández-Pardo ◽  
Fernando Cana ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Progression ◽  
Specific Treatment ◽  
Predictive Biomarkers ◽  
Liquid Biopsies ◽  
Cell Free Dna ◽  
Specific Patient ◽  
Free Dna ◽  
Potential Biomarker ◽  
Cancer Types

Bladder cancer (BC) is among the most frequent cancer types in the world and is the most lethal urological malignancy. Presently, diagnostic and follow-up methods for BC are expensive and invasive. Thus, the identification of novel predictive biomarkers for diagnosis, progression, and prognosis of BC is of paramount importance. To date, several studies have evidenced that cell-free DNA (cfDNA) found in liquid biopsies such as blood and urine may play a role in the particular scenario of urologic tumors, and its analysis may improve BC diagnosis report about cancer progression or even evaluate the effectiveness of a specific treatment or anticipate whether a treatment would be useful for a specific patient depending on the tumor characteristics. In the present review, we have summarized the up-to-date studies evaluating the value of cfDNA as potential diagnostic, prognostic, or monitoring biomarker for BC in several biofluids.

Pan-tumor analyses of kinase fusions detected in circulating tumor DNA (ctDNA) and concordance with paired tissue.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 3517-3517
Author(s):  
Jessica Kim Lee ◽  
Daniel Lieber ◽  
Russell Madison ◽  
Jon Chung ◽  
Alexa Betzig Schrock ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Median Time ◽  
Liquid Biopsy ◽  
Clinical Care ◽  
Driver Mutations ◽  
Gene Fusions ◽  
Sample Collection ◽  
Liquid Biopsies ◽  
Kinase Gene ◽  
Tissue Samples

3517 Background: Oncogenic kinase gene fusions are targetable with approved and investigational therapies and can also emerge as acquired resistance (AR) to targeted therapy. To understand the clinical validity of liquid biopsy comprehensive genomic profiling (CGP) to detect kinase fusions, we compared patient-matched plasma and tissue-based CGP. Methods: Hybrid capture-based CGP was performed on 28,743 plasma and 325,131 tumor tissue samples in the course of clinical care. Complete exonic regions of 13 kinases involved in oncogenic fusions plus select introns in ALK, EGFR, FGFR2/3, PDGFRA, RET, and ROS1 were sequenced to capture fusions with well characterized breakpoints. ctDNA fraction was estimated by maximum somatic allele frequency (MSAF). Results: 86% of cases had detectable ctDNA in plasma (MSAF > 0). Kinase fusions were detected in 2.1% of ctDNA cases (478/23,294) and were most prevalent in patients (pts) with bladder cancer (4.5%), non-small cell lung cancer (NSCLC) (4.3%), and cholangiocarcinoma (3.9%). The most commonly rearranged kinases were ALK (60%, 162/271) and RET (19%, 51/271) in NSCLC, FGFR2 (85%, 11/13) in cholangiocarcinoma, and FGFR3 (88%, 7/8) in bladder cancer. ALK fusions were detected in 26% (54/207) of fusion+ non-NSCLC cases. Paired tissue and ctDNA samples where ≥1 sample harbored a kinase fusion were available for 147 pts; median time between sample collection was 150 days (interquartile range: 444 days). Positive percent agreement (PPA) to tissue and liquid biopsies was 76% and 80%. Median MSAF in concordant and discordant ctDNA samples was 2.3% and 0.41% (p = 0.04) and median time between specimen collection for concordant and discordant pairs was 110 and 344 days (p = 0.04). PPA to tissue and liquid was 86% and 88% for pairs collected < 60 days apart (n = 53), versus 70% and 74% for pairs collected > 60 days apart. 6 pts with paired samples all collected > 196 days apart (median 593 days) had initial tissue samples with EGFR driver mutations and had an acquired kinase fusion (4 ALK, 1 FGFR2, 1 FGFR3) in the 2nd ctDNA sample, likely representing AR. Conclusions: Kinase gene fusions identified by tissue-based CGP were detected by liquid biopsy CGP in 85% of temporally-matched plasma samples. Kinase fusion detection by liquid biopsy CGP is feasible and had high PPA to tissue-based CGP. Subsequent sampling by liquid biopsy identified acquired fusions in EGFR driver positive cases consistent with known mechanisms of resistance to EGFR inhibitors suggesting utility of liquid biopsy at progression to identify targetable mechanisms of AR.

scholarly journals Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring

2018 ◽  
Vol 19 (9) ◽  
pp. 2514 ◽  
Author(s):  
Iris Lodewijk ◽  
Marta Dueñas ◽  
Carolina Rubio ◽  
Ester Munera-Maravilla ◽  
Cristina Segovia ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Liquid Biopsy ◽  
Disease Surveillance ◽  
Great Promise ◽  
Liquid Biopsies ◽  
Recurrence Rates ◽  
Invasive Approach ◽  
Non Invasive ◽  
Social Challenge ◽  
High Incidence

Bladder Cancer (BC) represents a clinical and social challenge due to its high incidence and recurrence rates, as well as the limited advances in effective disease management. Currently, a combination of cytology and cystoscopy is the routinely used methodology for diagnosis, prognosis and disease surveillance. However, both the poor sensitivity of cytology tests as well as the high invasiveness and big variation in tumour stage and grade interpretation using cystoscopy, emphasizes the urgent need for improvements in BC clinical guidance. Liquid biopsy represents a new non-invasive approach that has been extensively studied over the last decade and holds great promise. Even though its clinical use is still compromised, multiple studies have recently focused on the potential application of biomarkers in liquid biopsies for BC, including circulating tumour cells and DNA, RNAs, proteins and peptides, metabolites and extracellular vesicles. In this review, we summarize the present knowledge on the different types of biomarkers, their potential use in liquid biopsy and clinical applications in BC.

scholarly journals Urinary Cytology in the Diagnosis of Bladder Cancer

2021 ◽  
pp. 1-5
Author(s):  
R. B. Nerli ◽  
R. B. Nerli ◽  
Shadab Rangrez ◽  
Saziya Bidi ◽  
Shridhar C. Ghagane ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Tract ◽  
Urothelial Carcinoma ◽  
Urinary Cytology ◽  
Specific Method ◽  
Low Grade ◽  
Medical Procedure ◽  
High Grade ◽  
Exfoliated Cells ◽  
Criteria For Diagnosis

The examination of urine is an ancient medical procedure dating back thousands of years. Microscopic examination of cells in the urine is being done since the invention of microscope. Presently the cytological examination of urine or other fluid samples from the urinary tract is a routine non-invasive diagnostic procedure to detect cancer of the urinary tract, especially in patients with painless haematuria. It is also used in the follow-up of patients previously treated for bladder cancer to detect recurrence or a new primary. It is a highly specific method for the diagnosis of invasive and in situ urothelial carcinoma and high-grade papillary carcinoma. However, it is unreliable for the detection of low-grade papillary neoplasms. Malignant cytomorphological characteristics of the exfoliated cells in urine or bladder washing can facilitate the diagnosis of bladder cancer. The Paris System (TPS) Working Group has proposed. The Paris System (TPS) authorities have proposed a standard reporting stem which includes specified diagnostic categories and cytomorphologic criteria for diagnosis of High-grade Urothelial Carcinoma (HGUC).

518 Patient-derived sialyl-Tn positive invasive bladder cancer xenografts in nude mice: An exploratory model study

2014 ◽  
Vol 13 (1) ◽  
pp. e518 ◽  
Author(s):  
J.A. Ferreira ◽  
C. Bernardo ◽  
T. Amaro ◽  
C. Costa ◽  
P. Lopes ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Nude Mice ◽  
Invasive Bladder Cancer ◽  
Model Study ◽  
Sialyl Tn ◽  
Exploratory Model
Sign in / Sign up

Export Citation Format

Share Document